Thrombophilic patterns of coagulation factors in lupus

Lupus

Volumn 18, Issue 5, 2009, Pages 400-406

  Dhar, J Patricia ^a,b,f   Andersen, J ^e   Essenmacher, L ^a   Ager, J ^a   Bentley, G ^d   Sokol, R J ^b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DETROIT MEDICAL CENTER   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Haematologic changes; Lupus anticoagulant; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; FIBRINOGEN; HOMOCYSTEINE; LUPUS ANTICOAGULANT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE FUNCTION; THROMBOPHILIA; THROMBOSIS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD PLATELET DISORDERS; COHORT STUDIES; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICHIGAN; MIDDLE AGED; PREVALENCE; PROTHROMBIN; RETROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 63749111762     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308097566     Document Type: Article

References (27)

1. Cerera R Khamashta MA Font J et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308.
2. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145-151.
3. Male C Foulon D Hoogendoom H. et al. Predictive value of persistent versus transient antiphospholipid subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106: 4152-4158.
4. Nicolaides AN Breddin HK Carpenter P et al. Consensus statement: thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2005; 24: 1-26.
5. Andersen J. Sticky platelet syndrome. Clin Adv Hematol Oncol 2006; 4: 423-424.
6. Frenkel EP Mammen EF. Sticky platelet syndrome and thrombocythemia. Hematol Oncol Clin North Am 2003; 17: 63-83.
7. Mammen EF Barnhart M Selik NR Gilroy J Klepach GI. "Sticky Platelet Syndrome": A congenital platelet abnormality predisposing to thrombosis. Folia Haematol Int Mag Klin Morphol Blutforsch 1988; 115: 361-365.
8. Mammen EF. Sticky platelet syndrome. Semin Thromb Hemost 1999; 25: 361-365.
9. Pereira J Alfaro G Goycoolea M et al. Circulating platelet - derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 2006; 95: 94-99.
10. Nojima J Juratsune H Suehisa E Kitani T Iwatani Y Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and antiphosphatidylserine/prothrombin antibodies - Co-existance of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91: 967-976.
11. Ekdahl KN Bengtsson AA Andersson J et al. Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation. Br J Haematol 2004; 125: 74-78.
12. Levy Y Shenkman B Tamarin I. et al. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. Arthritis Rheum 2005; 52: 4011-4017.
13. Tan EM Cohen AS Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
14. Hochberg MC. [letter] Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
15. Detroit Medical Center University Laboratories Standard Policies and Procedures Manual. updated yearly, most recently; 2007.
16. Toloza SMA Uribe AG McGwin G.; for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA); XXIII, Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-3957.
17. Petri M. Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191-193.
18. Barcat D Guerin V Ryman A et al. Thrombophilia and thrombosis in systemic lupus erythematosus; a case control study. Ann Rheum Dis 2003; 62: 1016-1017.
19. 6Mok CC Tang SSK To CH Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus. A comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-2782.
20. Esdaile JM Abrahamowicz M Grodzicky T et al. Traditional risk Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
21. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction but not atherosclerosis: Hopkins lupus cohort. Thromb Res 2004; 114: 593-595.
22. Mackworth-Young CG. Antiphospholipid syndrome: Multiple mechanisms. Clin Exp Immunol 2004; 136: 393-401.
23. Petri M Perez-Gutthann S Spence D Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-519.
24. Matsuura E Koayashi K Hurley BL Lopez LR. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2006; 15: 478-483.
25. Joseph JE Harrison P Mackie IJ Isenberg DA Machin SJ. Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus, and rheumatoid arthritis. Br J Haematol 2001; 115: 451-459.
26. Martinuzzo ME Maclouf J Carreras LO Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671.
27. Vazques-Mellado J Llorente L Richaud-Patin Y Alarcon-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding of β2 glycoprotein I and through it that of IgG antiphospholipid antibodies: Studies thrombosis in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun 1994; 7: 335-348.